FDA Delays Decision on Ascendis’ Dwarfism Drug By Three Months
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
FDA Delays Decision on Ascendis’ Dwarfism Drug By Three Months Read More »
